BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//7.3.1//EN
TZID:America/Detroit
X-WR-TIMEZONE:America/Detroit
BEGIN:VEVENT
UID:45@amyloidosis.org
DTSTART;TZID=America/Chicago:20260729T180000
DTEND;TZID=America/Chicago:20260729T184500
DTSTAMP:20260602T135033Z
URL:https://amyloidosis.org/events/the-role-of-upfront-autologous-sct-for-
 primary-al-amyloidosis/
SUMMARY:The role of upfront autologous SCT for primary AL amyloidosis
DESCRIPTION:Webinar Session: Wednesday\, July 29th at 6 PM (ET) Zoom Meetin
 g\n\n(These sessions will not be recorded due to patient involvement and H
 IPAA laws)\n\nTo Register HERE\n\nThe role of upfront autologous SCT for 
 primary AL amyloidosis\n\nJoin us for an informative session with Dr. Tibo
 r Kovacsovics on the role of upfront autologous stem cell transplantation 
 in treating primary AL amyloidosis. Learn how this treatment may affect ou
 tcomes\, what patients can expect during the process\, and how it fits int
 o overall disease management. Helpful for patients and caregivers.\n\nDr. 
 Tibor Kovacsovics is Chief of Hematology and Medical Director of Leukemia 
 at City of Hope Cancer Center Phoenix. A hematologist-oncologist with 20 y
 ears of clinical research experience\, he specialises in AML\, ALL\, stem 
 cell transplantation\, and amyloidosis. He trained at Harvard Medical Scho
 ol/MGH/Brigham and Women's\, co-founded the Utah Amyloidosis Program at Hu
 ntsman Cancer Institute\, and has served as principal investigator on doze
 ns of landmark hematology studies.\n\n\n\nSpeaker: Tibor Kovacsovics\, MD\
 n\n\n\n\n
END:VEVENT
BEGIN:VTIMEZONE
TZID:America/Chicago
X-LIC-LOCATION:America/Chicago
BEGIN:DAYLIGHT
DTSTART:20260308T030000
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
END:DAYLIGHT
END:VTIMEZONE
END:VCALENDAR